Lineage Cell Therapeutics (LCTX) Q3 2026 earnings summary

Executive summary

• Acquired NeuroAirmid on November 12, adding worldwide rights to HUNT1, a Phase 1b/2a Huntington’s disease cell therapy; six participants had been dosed in REGEN4HD, with no serious adverse events reported.

• Advanced OpRegen, OPC1, COR1, ReSonance and manufacturing-platform programs alongside the HUNT1 acquisition.

Financial highlights

• Q3 2026 revenue was $1.434M versus $3.681M a year earlier, down 61%; lower Roche collaboration revenue and WDI services drove the decline.

• Q3 operating expenses were $8.748M versus $7.467M; operating loss widened to $7.314M from $3.786M.

• Q3 net income attributable to common shareholders was $4.232M versus a $29.781M loss; the result included a non-cash $11.944M warrant revaluation gain.

• Nine-month revenue was $4.228M versus $7.948M; operating loss was $23.830M versus $30.071M, and net income was $0.902M versus a $64.384M loss.

Outlook and guidance

• Cash, cash equivalents and marketable securities totaled $45.2M at September 30, 2026, and were expected to fund planned operations into Q2 2028.

• Initial COR1 preclinical functional-model data were expected in Q1 2027; a ReSonance development-planning meeting with Denmark’s medicines agency was being prepared for Q4 2026.

• HUNT1 clinical costs were estimated at less than $2M annually, with a CIRM award of up to $12M to UC Irvine and co-funding obligations of up to $3.1M.

• Operating losses were expected to continue for several years, with additional capital needed as development and regulatory work advances.